Structured endocrine surveillance identifies isolated ACTH deficiency during perioperative pembrolizumab for early triple- negative breast cancer
A retrospective study of 17 patients with early triple-negative breast cancer undergoing perioperative pembrolizumab revealed that structured endocrine surveillance identified isolated ACTH deficiency in nearly 30% of cases, highlighting that enhanced diagnostic intensity is crucial for detecting this underrecognized immune-related adverse event.
Original paper licensed under CC BY 4.0 (https://creativecommons.org/licenses/by/4.0/). This is an AI-generated explanation of the paper below. It is not written or endorsed by the authors. For technical accuracy, refer to the original paper. Read full disclaimer
Cancer treatment has entered a new era where the body's own immune system is trained to hunt down malignant cells. For a specific and aggressive type of breast cancer known as triple-negative breast cancer, doctors now often use a powerful drug called pembrolizumab alongside standard chemotherapy. This combination has proven effective at shrinking tumors before surgery and preventing their return afterward. However, because this drug supercharges the immune system, it can sometimes cause the body to turn against its own healthy tissues, a side effect known as an immune-related adverse event. One of the most critical systems that can be affected is the endocrine system, which acts as the body's chemical messaging network. Specifically, the pituitary gland in the brain sends signals to the adrenal glands to produce cortisol, a hormone essential for managing stress and maintaining energy. When the immune system mistakenly attacks the pituitary gland or the signals it sends, the body may stop producing enough cortisol, a condition that can be dangerous if left untreated. Distinguishing between the fatigue caused by chemotherapy and the fatigue caused by a failing hormone system is notoriously difficult, often leading to missed diagnoses.
Researchers at the Japanese Red Cross Shizuoka Hospital set out to see if a more careful, structured approach to checking hormone levels could reveal problems that might otherwise go unnoticed. They looked back at the medical records of seventeen patients with early-stage triple-negative breast cancer who had received this specific treatment regimen. The team did not wait for patients to report severe symptoms; instead, they proactively measured levels of a hormone called ACTH and cortisol at regular intervals throughout the treatment process. This method allowed them to catch subtle changes before they became critical. The results were striking. Among the seventeen patients, five developed a condition called isolated ACTH deficiency. In plain terms, this means the pituitary gland stopped sending the specific signal needed to tell the adrenal glands to make cortisol, while the rest of the pituitary's functions remained normal. This occurred in nearly thirty percent of the patients in this group, a rate significantly higher than what has been reported in large, broad clinical trials of the same drug.
The patients who developed this condition showed a range of symptoms, from fever and fatigue to dizziness and drowsiness. These symptoms appeared anywhere from fifty to two hundred forty-two days after the treatment began. In every case, the researchers confirmed the diagnosis by having an endocrinologist perform specialized stimulation tests, which involve giving the patient a substance that normally triggers hormone release to see if the body responds correctly. All five patients were then treated with hydrocortisone, a medication that replaces the missing cortisol. The outcome of this careful management was encouraging. Two of the patients were able to continue with their full course of post-surgery pembrolizumab treatment without interruption, simply by taking the hormone replacement. For the other three, the drug was stopped for various reasons, including patient preference or other severe side effects, but the diagnosis itself allowed for a clear understanding of their condition rather than leaving it as a mystery.
The study suggests that the frequency of this specific hormone problem may be much higher than currently believed, but only if doctors are looking for it with the right tools. The researchers noted that in their experience, the condition was often hidden because its symptoms overlap so closely with the general tiredness caused by chemotherapy. By intensifying their monitoring schedule after the first few cases were found, they were able to identify these issues early. The authors caution that because this was a small group of patients from a single hospital, the exact percentage they found should not be taken as a final rule for everyone. However, the findings strongly indicate that current methods of surveillance might be missing central adrenal dysfunction. The study concludes that with a more rigorous and structured approach to checking hormone levels, doctors can identify and treat these deficiencies, allowing more patients to safely complete their life-saving cancer therapies.
Drowning in papers in your field?
Get daily digests of the most novel papers matching your research keywords — with technical summaries, in your language.